Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Jack S. Bodner

Partner

New York +1 212 841 1079

  • About
  • Representative Matters
  • Credentials
  • About

    Jack Bodner is vice chair of Covington’s Corporate Group and is a leading M&A lawyer and trusted strategic adviser to boards of directors, special committees, and senior management teams on transformative transactions, with a particular focus on domestic and cross-border M&A transactions in the life sciences, media & entertainment and technology industries, as well as manufacturing, industrial and other industries. Jack represents pharmaceutical, biotechnology, medical device, medtech and diagnostic, and healthcare services companies on public and private acquisitions, divestitures, funding and option structures, reverse mergers, and de-SPAC transactions, and media & entertainment companies on deals involving music catalogues, NIL rights and other assets and production, content/IP and streaming and digital distribution. Jack helps clients execute their most important strategic initiatives while addressing the evolving legal, regulatory, governance, and market dynamics that can shape deal value and execution.

    He is widely recognized for guiding clients through complex, high-value transactions where intellectual property, innovation, and technology are key drivers of enterprise value. Drawing on more than 25 years of experience, clients rely on Jack not only for his deep transactional experience, but also for his pragmatic, commercially focused judgment to help them navigate critical strategic decisions, preserve and maximize value, minimize risk and uncertainty, and achieve successful outcomes.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • Nasdaq-listed Lantheus Holdings in its up to $8 billion announced sale to Curium.
    • BioCryst Pharmaceuticals in its $920 million acquisition of Nasdaq-listed Astria Therapeutics, Inc.
    • Terumo Medical in its $1.5 billion acquisition of OrganOx.
    • BioNTech SE in its announced $1.25 billion acquisition of Nasdaq-listed CureVac N.V.
    • Nasdaq-listed Lantheus Holdings in its $750 million acquisition of Life Molecular Imaging.
    • Global medical device company in its $475 million acquisition of an organ transport products and services company.
    • Music company in one of the largest music catalog deals in the music industry.
    • Nasdaq-listed Selecta Biosciences in its reverse merger with Cartesian Therapeutics.
    • Astellas Pharma in its strategic investment in Nasdaq-listed Taysha Gene Therapies.
    • SK Materials in its $200 million strategic investment in 8 Rivers Capital, a carbon capture, usage and storage technology company.
    • NewAmsterdam Pharma in going-public deSPAC merger with Frazier Life Sciences.
    • Global medical device company in its $320 million acquisition of a U.S.-based infection control and instrument care consumables company.
    • NYSE listed Adit Edtech Acquisition Corp in its $3.3 billion all stock merger with GRIID Infrastructure, a vertically integrated bitcoin mining company.
    • U.S. cable network in the potential acquisition of several US-based production companies.
    • BioNTech in its acquisition of Nasdaq-listed Neon Therapeutics.
    • China Grand Pharmaceutical and Healthcare Holding and Sirtex Medical US Holdings in connection with a strategic controlling investment in Nasdaq-listed OncoSec Medical.
    • First Wave Bio in its merger with Nasdaq-listed AzurRx BioPharma.
    • NYSE-listed Graham Holdings in its $323 million acquisition of NYSE-listed Leaf Group.

    • Humacyte in its $1.1 billion merger with Nasdaq-listed Alpha Healthcare Acquisition Corp.
    • Marathon Asset Management in its $310 million acquisition of Kaleo, a pharmaceutical company specializing in injectors to treat allergic anaphylaxis and opioid overdoses.
    • Northern Biologics in the sale of its Periostin and Flt3 programs to Boehringer Ingelheim.
    • SK Innovation in its $13 billion joint venture with Ford Motor Company to manufacture electric vehicle batteries.
    • Twig Education in its sale to Weld North Education.
    • Financial services company in connection with its sale of certain commodities indices to a financial data company.
    • Oxford BioMedica in a carve-out transaction involving Nasdaq-listed Homology Medicine’s AAV manufacturing and innovation business and $180 million sale to OXB.
    • King Pharma in its $3.6 billion sale of Nasdaq-listed King Pharma to Pfizer.
    • Nasdaq-listed Progenics, as special counsel to the Board of Directors, in its $500 million sale to Lantheus.
    • Nasdaq-listed Entasis Therapeutics in connection with its sale to Innoviva.
    • IFM Therapeutics:
      • in the sale of IFM’s NLRP3 antagonist programs to Novartis for up to $1.275 billion;
      • in the sale of IFM’s STING and NLRP3 agonist programs to BMS for up to $1.3 billion; and
      • in a collaboration and option transaction with Novartis in connection with cGAS/STING-related immunotherapies, with an option value of up to $840 million.
    • Novo Nordisk:
      • in its acquisition of a manufacturing facility from Purdue Pharma; and
      • in its acquisition of a tropical disease Priority Review Voucher from Medicines Development for Global Health.
    • Astellas Pharma in its $385 million acquisition of Nasdaq-listed Ocata Therapeutics, a biotechnology company specializing in the development of stem cell-based treatments in regenerative medicine.
    • Illumina, Inc.:
      • in its announced $1.2 billion acquisition of Pacific Biosciences;
      • in its up to $450 million acquisition of Verinata Health, Inc.;
      • in its acquisition of NextBio; and
      • in its creation of a joint venture with Warburg Pincus and Sutter Hill Ventures focused on accelerating consumer adoption of genomics.
    • SK Holdings and SK Biotek Co., Ltd., in the acquisition of a small molecule active pharmaceutical ingredient manufacturing facility from BMS.
    • Oxford Immunotec:
      • in its $591 million Sale of Nasdaq-listed Oxford Immunotec to PerkinElmer;
      • in its acquisition of Imugen, Inc.;
      • in its acquisition of Immunetics, Inc.; and
      • in its $170 million sale of its U.S. laboratory services business to Quest Diagnostics.
    • Reliance Industries Limited in its $75 million acquisition of NYSE-listed Radisys Corporation.
    • Fiberon in its $470 million sale to Fortune Brands Home & Security.
    • GlaxoSmithKline in its the acquisition of ex-U.S. rights relating to the Quell wearable pain relief technology from with NeuroMetrix, Inc..
    • Famy Care Limited in the $750 million sale of its women's health business to Mylan Laboratories.
    • Oplink Communications in its $445 million sale to Koch Industries.
    • Metro Athletic Medicine & Fitness in the sale of its non-clinical assets to Pharos Capital. 
    • Lightbridge Communications, an independent global provider of network engineering services to the telecommunications industry, in its $240 million sale to Tech Mahindra.
    • The Walt Disney Company:
      • in its $5.3 billion acquisition of Fox Family Worldwide;
      • in its acquisition of Instafluence;
      • in its acquisition of India's UTV Software Communications Limited; and
      • in its acquisition of assets of The Jim Henson Company, Inc. (Muppets and Bear in the Big Blue House).
    • OptiSolar in the $400 million sale of its project development business to First Solar, Inc.
    • Asuragen in the sale of its miRInform® Thyroid and Pancreas test assets to Interpace Diagnostics, a subsidiary of PDI, Inc.
    • Assurant in its acquisition of Mobile Defense, a technology company focused on mobile device diagnostics and data processing for user assistance and predictive forecasting.
    • Broadridge Financial Solutions in its acquisition of technology assets of INVeSHARE to develop blockchain applications for Broadridge’s proxy business.
    • Autogrill S.p.A. in the spin-off and sale of the U.S. airport retail concession business from HMSHost Corporation to World Duty Free Group.
    • Mainfreight Limited in its acquisition of AMEX-listed Target Logistics.
    • Lottomatica S.p.A. in its $4.8 billion acquisition of GTECH Holdings Corporation, a publicly listed lottery and gaming technology company.
    • Financial Federal Corporation in its $738 merger with People’s United Financial.
    • B. Riley Financial in its acquisition of MK Capital Advisors.
    • Gannett Broadcasting in its formation and broadcasting of the Justice Network, a digital multicast channel devoted to law enforcement-related programming.
    • Faros Trading in the sale of a controlling interest to FXCM Inc.  
    • A U.S.-based medical devices company in its acquisition and related long-term license of a spinal device from a privately-held medical devices company, involving an upfront payment of cash together with a series of milestone payments.           
    • Trustmark Corporation in its sale of eight mutual fund portfolios of the Performance Funds Trust to Federated Investors Inc.
    • Gleacher & Company, Inc. in the sale of substantially all of the assets of its ClearPoint subsidiary to Homeward Residential, Inc., a wholly owned subsidiary of Ocwen Financial.
    • Saddle Gold in its sale to Premier Gold Mines.
    • UBS Securities LLC on the sale of a portfolio of interests in selected private equity funds to an investment firm.
    • Van Wagner in connection with Clear Channel’s acquisition of Van Wagner’s European billboard business.
    • Fiber Composites in its acquisition of Louisiana-Pacific Corporation's WeatherBest decking and railing business, and manufacturing and distribution facility in Meridian, Idaho.  
    • Metropolitan Intercollegiate Basketball Association in connection with the NCAA’s acquisition of the NIT.
    • Intergen (North America), Inc. in connection with Harbert Distressed Investment Master Fund, Ltd.’s acquisition of the Mayflower, Cottonwood & Redbud Projects.
    • LifePoint Hospitals in connection with LifePoint’s $1.7 billion acquisition of Province Healthcare Company.  
    • Burns, Philp & Company in the $1.35 billion sale of its yeast and bakery ingredient lines and Tone Brothers herbs and spices line to Associated British Food.
    • Special Committee of the Board of Directors of Covansys Corporation in connection with Fidelity Information Services Inc.’s $356 million acquisition of an interest in Covansys.
    • Special Committee of the Board of Directors of barnesandnoble.com inc. in its $513 million sale to Barnes & Noble, Inc.
    • Zimmer Holdings, Inc. in connection with its unsolicited $3.5 billion acquisition of Centerpulse AG and InCentive AG.
    • Triad Hospitals in connection with its $2.2 billion acquisition of Quorum Health Group.
    • Novartis Pharma AG in connection with its $1.6 billion acquisition of the pharmaceutical products Famvir® and Denavir® from SmithKline Beecham plc.

    Areas of Expertise

  • Credentials
    Education
    • New York University School of Law, J.D.
        • Order of the Coif
    • New York University, B.A.
        • magna cum laude
        • Phi Beta Kappa
    Bar Admissions
    • New York
    Accolades
    • Chambers USA, Corporate/M&A (2016-2017) 
    • Legal 500 US, Energy: Renewable/Alternative (2016); M&A: Commercial Deals and Contracts (2016); M&A: Large Deals (2012-2014); Energy: Regulatory (2014)    

    Areas of Expertise

News and Insights

Events